Skip to content

NIH-NIAID K01AI125726 (PI: Davidson)

Genetic Epidemiology of Nontuberculous Mycobacteria for Predicting Host Specificity and Lung Disease Outcomes

Goal: Identify genetic variations in nontuberculous mycobacteria infecting cystic fibrosis (CF) and non-CF patients that are predictive of host specificity, lung disease progression and response to antibiotic treatment.


Vertex Research Innovation Award in Cystic Fibrosis (PI: Davidson)

Genomic Evolution of Nontuberculous Mycobacteria During Cystic Fibrosis Airway Infection

Goal: Identify genomic features and evolutionary trajectories in longitudinally sampled CF-NTM isolates that are associated with clinical outcomes including development of active lung disease and treatment response.


Bill and Melinda Gates Foundation (PI: Walter)

A pathogen-targeted RNAseq method for monitoring treatment responses in human tuberculosis

Goal: Develop a new, culture-independent method of measuring the effectiveness of tuberculosis treatment in humans.
Role: Co-Investigator


Cystic Fibrosis Foundation (PI: Nick)

Molecular Basis for Combination Drug Failure in the Treatment of NTM

Goal: Identify and validate a transcriptomic signature for azithromycin-induced antagonism of amikacin in well-phenotyped Mycobacterium abscessus isolates from CF patients.
Role: Co-Investigator


Cystic Fibrosis Foundation (PI: Nick)

Cross-platform Comparison of Novel Markers of NTM in the CF Airway

Goal: Test the sensitivity and specificity of a suite of culture-independent markers of NTM, compared to standard sputum culture, and correlate with patient NTM phenotype.
Role: Co-Investigator